JP2017512789A - ジヒドロピリミジン化合物及び医薬におけるその適用 - Google Patents

ジヒドロピリミジン化合物及び医薬におけるその適用 Download PDF

Info

Publication number: JP2017512789A
Authority: JP; Japan
Prior art keywords: compound; mmol; methyl; thiazol; title compound
Prior art date: 2014-03-28
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP2016558407A

Other languages

English (en)

Japanese (ja)

Other versions

JP2017512789A5 (2

Inventor

ジャン、インジュン

レン、キンユン

リウ、シンチャン

ゴールドマン、ジークフリート

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Sunshine Lake Pharma Co Ltd

Original Assignee

Sunshine Lake Pharma Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-03-28

Filing date

2015-03-27

Publication date

2017-05-25

2015-03-27 Application filed by Sunshine Lake Pharma Co Ltd filed Critical Sunshine Lake Pharma Co Ltd

2017-05-25 Publication of JP2017512789A publication Critical patent/JP2017512789A/ja

2018-04-19 Publication of JP2017512789A5 publication Critical patent/JP2017512789A5/ja

Status Pending legal-status Critical Current

Links

QXIAGKWWKMKVLE-VIFPVBQESA-N CC(C)(C)OC(N1C[C@H](CCC(O)=O)OCC1)=O Chemical compound CC(C)(C)OC(N1C[C@H](CCC(O)=O)OCC1)=O QXIAGKWWKMKVLE-VIFPVBQESA-N 0.000 description 1
DYGCSUICELQJIO-COBSHVIPSA-N CC(C[C@H]1OCCNC1)C(O)=O Chemical compound CC(C[C@H]1OCCNC1)C(O)=O DYGCSUICELQJIO-COBSHVIPSA-N 0.000 description 1
0 CC(C[C@]1OCC[Zn]C1)C(*)=O Chemical compound CC(C[C@]1OCC[Zn]C1)C(*)=O 0.000 description 1
OGUVUOIKRVWUDL-ZDUSSCGKSA-N CC(NC(c1ncc[s]1)=N[C@H]1c(c(Cl)c2)ccc2Cl)=C1C(OC)=O Chemical compound CC(NC(c1ncc[s]1)=N[C@H]1c(c(Cl)c2)ccc2Cl)=C1C(OC)=O OGUVUOIKRVWUDL-ZDUSSCGKSA-N 0.000 description 1
ZRKFCDVMSWDCFX-UHFFFAOYSA-N CCC(C)CCCC(C(C)I)[ClH]CC Chemical compound CCC(C)CCCC(C(C)I)[ClH]CC ZRKFCDVMSWDCFX-UHFFFAOYSA-N 0.000 description 1
ILFIXUVIBJYIDE-VFNWGFHPSA-N CCOC(C1=C(CN2C[C@@H](CCC(O)=O)OCC2)NC(c2ncc[s]2)=N[C@H]1c(ccc(F)c1)c1Br)=O Chemical compound CCOC(C1=C(CN2C[C@@H](CCC(O)=O)OCC2)NC(c2ncc[s]2)=N[C@H]1c(ccc(F)c1)c1Br)=O ILFIXUVIBJYIDE-VFNWGFHPSA-N 0.000 description 1
XOYWJUFEMRHPBF-VFNWGFHPSA-N CCOC(C1=C(CN2C[C@@H](CCC(O)=O)OCC2)NC(c2ncc[s]2)=N[C@H]1c1ccccc1Cl)=O Chemical compound CCOC(C1=C(CN2C[C@@H](CCC(O)=O)OCC2)NC(c2ncc[s]2)=N[C@H]1c1ccccc1Cl)=O XOYWJUFEMRHPBF-VFNWGFHPSA-N 0.000 description 1
GTVGTNQWQJLDEG-BTYIYWSLSA-N CCOC(C1=C(CN2[C@@H](CCC(O)=O)COCC2)NC(c2ncc[s]2)=N[C@H]1c(ccc(F)c1)c1Br)=O Chemical compound CCOC(C1=C(CN2[C@@H](CCC(O)=O)COCC2)NC(c2ncc[s]2)=N[C@H]1c(ccc(F)c1)c1Br)=O GTVGTNQWQJLDEG-BTYIYWSLSA-N 0.000 description 1
KJKXMYQMOZCMRZ-VXGBXAGGSA-N CCOC(CC[C@H]([C@@H](C)OCC1)N1C(OC(C)(C)C)=O)=O Chemical compound CCOC(CC[C@H]([C@@H](C)OCC1)N1C(OC(C)(C)C)=O)=O KJKXMYQMOZCMRZ-VXGBXAGGSA-N 0.000 description 1
ONELXRQCJBCEOV-ZDUSSCGKSA-N COC(C1=C(CBr)NC(c2ncc[s]2)=N[C@H]1c(ccc(F)c1)c1Cl)=O Chemical compound COC(C1=C(CBr)NC(c2ncc[s]2)=N[C@H]1c(ccc(F)c1)c1Cl)=O ONELXRQCJBCEOV-ZDUSSCGKSA-N 0.000 description 1
CCVSZMHYKHZCJN-JLTOFOAXSA-N COC(C1=C(CN2C[C@@H](CCC(O)=O)OCC2)NC(c2ncc[s]2)=N[C@@H]1c(c(Cl)c1)ccc1F)=O Chemical compound COC(C1=C(CN2C[C@@H](CCC(O)=O)OCC2)NC(c2ncc[s]2)=N[C@@H]1c(c(Cl)c1)ccc1F)=O CCVSZMHYKHZCJN-JLTOFOAXSA-N 0.000 description 1
SKHFPNFIHFVECE-VLIAUNLRSA-N COC(C1=C(CN2C[C@@H](CCC(O)=O)OCC2)NC(c2ncc[s]2)=N[C@H]1c(c(Br)c1)ccc1F)=O Chemical compound COC(C1=C(CN2C[C@@H](CCC(O)=O)OCC2)NC(c2ncc[s]2)=N[C@H]1c(c(Br)c1)ccc1F)=O SKHFPNFIHFVECE-VLIAUNLRSA-N 0.000 description 1
BWVKMHFWCULXRS-VLIAUNLRSA-N COC(C1=C(CN2C[C@@H](CCC(O)=O)OCC2)NC(c2ncc[s]2)=N[C@H]1c1ccccc1Cl)=O Chemical compound COC(C1=C(CN2C[C@@H](CCC(O)=O)OCC2)NC(c2ncc[s]2)=N[C@H]1c1ccccc1Cl)=O BWVKMHFWCULXRS-VLIAUNLRSA-N 0.000 description 1
HJLJZZITBHJBPM-FPSMJMQUSA-N C[C@@H]1OCCN(CC(NC(c2ncc[s]2)=N[C@H]2c(c(Cl)c3)ccc3F)=C2C(OC)=O)[C@H]1CCC(O)=O Chemical compound C[C@@H]1OCCN(CC(NC(c2ncc[s]2)=N[C@H]2c(c(Cl)c3)ccc3F)=C2C(OC)=O)[C@H]1CCC(O)=O HJLJZZITBHJBPM-FPSMJMQUSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Virology (AREA)
Engineering & Computer Science (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biotechnology (AREA)
Gastroenterology & Hepatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)

JP2016558407A 2014-03-28 2015-03-27 ジヒドロピリミジン化合物及び医薬におけるその適用 Pending JP2017512789A (ja)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
CN201410126202.0		2014-03-28
CN201410126202		2014-03-28
CN201410596489.3		2014-10-29
CN201410596489		2014-10-29
PCT/CN2015/075299 WO2015144093A1 (en)	2014-03-28	2015-03-27	Dihydropyrimidine compounds and their application in pharmaceuticals

Publications (2)

Publication Number	Publication Date
JP2017512789A true JP2017512789A (ja)	2017-05-25
JP2017512789A5 JP2017512789A5 (2)	2018-04-19

Family

ID=54160517

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2016558407A Pending JP2017512789A (ja)	2014-03-28	2015-03-27	ジヒドロピリミジン化合物及び医薬におけるその適用

Country Status (12)

Country	Link
US (1)	US9771358B2 (2)
EP (1)	EP3122747B1 (2)
JP (1)	JP2017512789A (2)
KR (1)	KR20160133563A (2)
CN (1)	CN104945395B (2)
AU (1)	AU2015236982B2 (2)
CA (1)	CA2938050A1 (2)
MX (1)	MX2016012573A (2)
MY (1)	MY196243A (2)
RU (1)	RU2682672C2 (2)
SG (1)	SG11201605896WA (2)
WO (1)	WO2015144093A1 (2)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20200032098A (ko) *	2017-06-26	2020-03-25	노스 앤드 사우스 브라더 파마시 인베스트먼트 컴파니 리미티드	디하이드로피리미딘 화합물 및 약제에서의 이의 용도
JP2021523880A (ja) *	2018-05-16	2021-09-09	シチュアンケルン−バイオテックバイオファーマシューティカルカンパニーリミテッド	ジヒドロピリミジン化合物の固体形態及びその調製方法及びその使用

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR112014015197A8 (pt)	2011-12-21	2017-06-13	Novira Therapeutics Inc	agentes antivirais de hepatite b
KR102271574B1 (ko)	2012-08-28	2021-07-01	얀센 사이언시즈 아일랜드 언리미티드 컴퍼니	설파모일-아릴아미드 및 b형 간염 치료제로서의 그 용도
WO2014131847A1 (en)	2013-02-28	2014-09-04	Janssen R&D Ireland	Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
MX353412B (es)	2013-04-03	2018-01-10	Janssen Sciences Ireland Uc	Derivados de n-fenil-carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
DK2997019T3 (en)	2013-05-17	2018-12-03	Janssen Sciences Ireland Uc	SULFAMOYLTHIOPHENAMIDE DERIVATIVES AND USE THEREOF AS MEDICINES FOR TREATING HEPATITIS B
TWI733288B (zh)	2013-05-17	2021-07-11	愛爾蘭商健生科學愛爾蘭無限公司	胺磺醯基吡咯醯胺衍生物及其作為用於治療ｂ型肝炎藥物的用途
HRP20180791T1 (hr)	2013-07-25	2018-09-07	Janssen Sciences Ireland Uc	Glioksamid supstituirani derivati pirolamida i njihova uporaba kao lijekova za liječenje hepatitisa b
CA2923712C (en)	2013-10-23	2021-11-02	Janssen Sciences Ireland Uc	Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
KR102284938B1 (ko)	2013-11-27	2021-08-02	선샤인 레이크 파르마 컴퍼니 리미티드	다이하이드로피리미딘 유도체 및 이의 중간산물의 제조 방법
US9169212B2 (en)	2014-01-16	2015-10-27	Novira Therapeutics, Inc.	Azepane derivatives and methods of treating hepatitis B infections
US10392349B2 (en)	2014-01-16	2019-08-27	Novira Therapeutics, Inc.	Azepane derivatives and methods of treating hepatitis B infections
CA2936947A1 (en)	2014-02-05	2015-08-13	Novira Therapeutics, Inc.	Combination therapy for treatment of hbv infections
TW201620893A (zh)	2014-02-06	2016-06-16	健生科學愛爾蘭無限公司	磺醯胺基吡咯醯胺衍生物及其用作治療ｂ型肝炎之醫藥品的用途
JP2018510159A (ja)	2015-03-19	2018-04-12	ノヴィラ・セラピューティクス・インコーポレイテッド	アゾカン及びアゾナン誘導体及びｂ型肝炎感染症の治療法
US10442788B2 (en)	2015-04-01	2019-10-15	Enanta Pharmaceuticals, Inc.	Hepatitis B antiviral agents
WO2016183266A1 (en)	2015-05-13	2016-11-17	Enanta Pharmaceuticals, Inc.	Ehpatitis b antiviral agents
US10875876B2 (en)	2015-07-02	2020-12-29	Janssen Sciences Ireland Uc	Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US10179131B2 (en)	2015-07-13	2019-01-15	Enanta Pharmaceuticals, Inc.	Hepatitis B antiviral agents
US10301255B2 (en)	2015-07-22	2019-05-28	Enanta Pharmaceuticals, Inc.	Hepatitis B antiviral agents
TW201718496A (zh)	2015-09-29	2017-06-01	諾維拉治療公司	B型肝炎抗病毒劑之晶型
WO2017136403A1 (en)	2016-02-02	2017-08-10	Enanta Pharmaceuticals, Inc.	Hepatitis b antiviral agents
KR102398439B1 (ko)	2016-03-07	2022-05-16	이난타 파마슈티칼스, 인코포레이티드	B형 간염 항바이러스제
AU2017248828A1 (en)	2016-04-15	2018-11-01	Janssen Sciences Ireland Uc	Combinations and methods comprising a capsid assembly inhibitor
CN107400125B (zh) *	2016-05-19	2020-02-11	广东东阳光药业有限公司	二氢嘧啶衍生物的晶型、盐和复合物及其在药物中的应用
CA3028228A1 (en)	2016-06-10	2017-12-14	Enanta Pharmaceuticals, Inc.	Hepatitis b antiviral agents
CN107674072B (zh) *	2016-08-01	2020-11-24	广东东阳光药业有限公司	二氢嘧啶衍生物及其酸加成物的制备方法
WO2018090862A1 (zh)	2016-11-18	2018-05-24	四川科伦博泰生物医药股份有限公司	二氢嘧啶类化合物及其制备方法和用途
US11166954B2 (en)	2016-11-18	2021-11-09	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	Dihydropyrimidine compound and preparation method and use thereof
AU2018291688B2 (en)	2017-06-27	2022-02-03	Janssen Pharmaceutica Nv	Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections
SG11202001685TA (en)	2017-08-28	2020-03-30	Enanta Pharm Inc	Hepatitis b antiviral agents
EA202091113A1 (ru)	2017-11-02	2020-08-28	Айкурис Гмбх Унд Ко. Кг	Новые высокоактивные аминотиазолзамещенные индол-2-карбоксамиды, активные в отношении вируса гепатита b (hbv)
KR20200083552A (ko)	2017-11-02	2020-07-08	아이쿠리스 게엠베하 운트 코. 카게	B형 간염 바이러스 (hbv)에 활성인 신규 고활성 피라졸로-피페리딘 치환된 인돌-2-카르복스아미드
WO2019113173A1 (en)	2017-12-06	2019-06-13	Enanta Pharmaceuticals, Inc.	Hepatitis b antiviral agents
WO2019113175A1 (en)	2017-12-06	2019-06-13	Enanta Pharmaceuticals, Inc.	Hepatitis b antiviral agents
US11058678B2 (en)	2018-01-22	2021-07-13	Enanta Pharmaceuticals, Inc.	Substituted heterocycles as antiviral agents
MX2020009531A (es)	2018-03-14	2020-10-05	Janssen Sciences Ireland Unlimited Co	Regimen posologico del modulador del ensamblaje de la capside.
WO2019191166A1 (en)	2018-03-29	2019-10-03	Enanta Pharmaceuticals, Inc.	Hepatitis b antiviral agents
CN109021015B (zh) *	2018-07-12	2019-12-03	山东大学	二氢嘧啶-磷酰胺类衍生物及其制备方法与应用
US11053235B2 (en)	2018-08-09	2021-07-06	Janssen Sciences Ireland Unlimited Company	Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases
JP2022500466A (ja)	2018-09-21	2022-01-04	エナンタファーマシューティカルズインコーポレイテッド	抗ウイルス剤としての官能化複素環
AR116946A1 (es)	2018-11-02	2021-06-30	Aicuris Gmbh & Co Kg	Derivados de urea 6,7-dihidro-4h-pirazolo[4,3-c]piridinas activas contra el virus de la hepatitis b (vhb)
WO2020089460A1 (en)	2018-11-02	2020-05-07	Aicuris Gmbh & Co. Kg	Novel urea 6,7-dihydro-4h-thiazolo[5,4-c]pyridines active against the hepatitis b virus (hbv)
AR117189A1 (es)	2018-11-02	2021-07-21	Aicuris Gmbh & Co Kg	Derivados de 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activos contra el virus de la hepatitis b (vhb)
PY1991611A (es)	2018-11-02	2022-03-14	Aicuris Gmbh & Co Kg	Nueva urea 6,7-dihidro-4h-pirazolo [1,5-a] pirazinas activas contra el virus de la hepatitis b (vhb)
PY1991603A (es)	2018-11-02	2020-09-17	Aicuris Gmbh & Co Kg	Nueva 6,7-dihidro-4h-pirazolo [1,5-a] pirazina indole -2-carboxamidas activas contra el virus de la hepatitis b (vhb)
UY38437A (es)	2018-11-02	2020-05-29	Aicuris Gmbh & Co Kg	Nuevas urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas activas contra el virus de la hepatitis b (hbv)
IL283190B2 (en)	2018-11-21	2025-08-01	Enanta Pharm Inc	Functionalized heterocycles as antiviral agents
TW202035412A (zh) *	2018-12-20	2020-10-01	比利時商健生藥品公司	雜芳基二氫嘧啶衍生物和治療ｂ型肝炎感染之方法
WO2020169784A1 (en)	2019-02-22	2020-08-27	Janssen Sciences Ireland Unlimited Company	Amide derivatives useful in the treatment of hbv infection or hbv-induced diseases
BR112021021564A2 (pt)	2019-04-30	2022-01-04	Aicuris Gmbh & Co Kg	Indol-2-carboxamidas inovadoras ativas contra o vírus da hepatite b (hbv)
US20220227785A1 (en)	2019-04-30	2022-07-21	Aicuris Gmbh & Co. Kg	Novel phenyl and pyridyl ureas active against the hepatitis b virus (hbv)
JP2022533008A (ja)	2019-04-30	2022-07-21	アイクリスゲゼルシャフトミットベシュレンクテルハフツングウントコンパニーコマンディトゲゼルシャフト	Ｂ型肝炎ウイルス（ｈｂｖ）に対し活性な新規のオキサリルピペラジン
WO2020221824A1 (en)	2019-04-30	2020-11-05	Aicuris Gmbh & Co. Kg	Novel indolizine-2-carboxamides active against the hepatitis b virus (hbv)
AR119732A1 (es)	2019-05-06	2022-01-05	Janssen Sciences Ireland Unlimited Co	Derivados de amida útiles en el tratamiento de la infección por vhb o de enfermedades inducidas por vhb
WO2020247444A1 (en)	2019-06-03	2020-12-10	Enanta Pharmaceuticals, Inc,	Hepatitis b antiviral agents
WO2020247561A1 (en)	2019-06-04	2020-12-10	Enanta Pharmaceuticals, Inc,	Hepatitis b antiviral agents
WO2020247575A1 (en)	2019-06-04	2020-12-10	Enanta Pharmaceuticals, Inc.	Hepatitis b antiviral agents
US20220249647A1 (en) *	2019-06-18	2022-08-11	Janssen Sciences Ireland Unlimited Company	Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators
US11738019B2 (en)	2019-07-11	2023-08-29	Enanta Pharmaceuticals, Inc.	Substituted heterocycles as antiviral agents
US11236108B2 (en)	2019-09-17	2022-02-01	Enanta Pharmaceuticals, Inc.	Functionalized heterocycles as antiviral agents
CN110615797A (zh) *	2019-10-11	2019-12-27	李丽丽	用于治疗乙型肝炎的化合物及其用途
WO2021188414A1 (en)	2020-03-16	2021-09-23	Enanta Pharmaceuticals, Inc.	Functionalized heterocyclic compounds as antiviral agents
EP4263535A1 (en)	2020-12-17	2023-10-25	Astrazeneca AB	N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- quinoline-4-carboxamides
EP4289842A4 (en)	2021-02-05	2025-01-08	Hepagene Therapeutics (HK) Limited	Phenyldihydropyrimidine compound and use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2014029193A1 (en) *	2012-08-24	2014-02-27	Sunshine Lake Pharma Co., Ltd.	Dihydropyrimidine compounds and their application in pharmaceuticals
WO2014037480A1 (en) *	2012-09-10	2014-03-13	F. Hoffmann-La Roche Ag	6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS61271278A (ja)	1985-05-20	1986-12-01	イ−　ア−ル　スクイブ　アンド　サンズ　インコ−ポレ−テツド	２−置換チオまたはオキソ−４−アリ−ルまたはヘテロシクロ−５−カルボキシ−１，４−ジヒドロピリミジン
GB8906168D0 (en)	1989-03-17	1989-05-04	Pfizer Ltd	Therapeutic agents
SE9702564D0 (sv)	1997-07-02	1997-07-02	Astra Ab	New compounds
SE9702563D0 (sv)	1997-07-02	1997-07-02	Astra Ab	Compounds
DE19817264A1 (de)	1998-04-18	1999-10-21	Bayer Ag	Neue Dihydropyrimidine
DE19817262A1 (de)	1998-04-18	1999-10-21	Bayer Ag	Neue 2-heterocyclisch substituierte Dihydropyrimidine
DE19817265A1 (de)	1998-04-18	1999-10-21	Bayer Ag	Verwendung von Dihydropyrimidinen als Arzneimittel und neue Stoffe
WO2000058302A1 (de)	1999-03-25	2000-10-05	Bayer Aktiengesellschaft	Dihydropyrimidine und ihre verwendung zur behandlung von hepatitis b
DE10012549A1 (de)	2000-03-15	2001-09-20	Bayer Ag	Arzneimittel gegen virale Erkrankungen
DE10012824A1 (de)	2000-03-16	2001-09-20	Bayer Ag	Arzneimittel gegen virale Erkrankungen
DE10012823A1 (de)	2000-03-16	2001-09-20	Bayer Ag	Arzneimittel gegen virale Erkrankungen
DE10013125A1 (de)	2000-03-17	2001-09-20	Bayer Ag	Arzneimittel gegen virale Erkrankungen
DE10013126A1 (de)	2000-03-17	2001-09-20	Bayer Ag	Arzneimittel gegen virale Erkrankungen
US7157461B2 (en)	2003-07-23	2007-01-02	Bristol-Myers Squibb Co.	Substituted dihydropyrimidine inhibitors of calcium channel function
CN101104604B (zh)	2006-07-10	2011-03-02	北京摩力克科技有限公司	光学纯二氢嘧啶类化合物及其用于制备治疗和预防病毒性疾病的药物的用途
CN101104617B (zh)	2006-07-10	2010-06-23	北京摩力克科技有限公司	二氢嘧啶类化合物及其用于制备治疗和预防病毒性疾病的药物的用途
CN101225084A (zh)	2007-01-16	2008-07-23	北京摩力克科技有限公司	二氢嘧啶类化合物及其用于制备治疗和预防病毒性疾病的药物的用途
CN101328170B (zh)	2007-06-18	2011-09-14	张中能	一种氟苯基-取代噻唑二氢嘧啶
WO2008154819A1 (fr)	2007-06-18	2008-12-24	Zhang, Zhongneng	Thiazolyl-dihydropyrimidines à substitution carbéthoxy
AU2008265397C1 (en)	2007-06-18	2013-08-29	Sunshine Lake Pharma Co., Ltd.	Bromo-phenyl substituted thiazolyl dihydropyrimidines
WO2008154820A1 (fr)	2007-06-18	2008-12-24	Zhang, Zhongneng	Thiazolyl-dihydropyrimidines à substitution carbéthoxy
WO2010069147A1 (zh)	2008-12-17	2010-06-24	张中能	二氢嘧啶类化合物、其组合物及其应用
CN101744823B (zh)	2008-12-17	2013-06-19	广东东阳光药业有限公司	一种二氢嘧啶类化合物的固体分散体及其药用制剂
CN101575318B (zh)	2009-06-25	2012-02-08	中国人民解放军军事医学科学院毒物药物研究所	二氢嘧啶类化合物及其用于制备治疗和/或预防病毒性疾病的药物的用途
US9487534B2 (en)	2011-08-02	2016-11-08	Scripps Research Institute, A Not-For-Profit Public Benefit Corporation Of California	Modulators of virus assembly as antiviral agents
EP2800742B1 (en)	2012-01-06	2016-04-06	Janssen Sciences Ireland UC	4,4-disubstituted-1,4-dihydropyrimidines and the use thereof as medicaments for the treatment of hepatitis b
US20130267517A1 (en)	2012-03-31	2013-10-10	Hoffmann-La Roche Inc.	Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
CN103664897B (zh)	2012-09-01	2018-04-03	广东东阳光药业有限公司	二氢嘧啶类化合物及其在药物中的应用
CN103664925B (zh)	2012-09-07	2018-01-23	广东东阳光药业有限公司	杂芳基取代的二氢嘧啶类化合物及其在药物中的应用
CN103664899B (zh)	2012-09-11	2017-06-16	广东东阳光药业有限公司	杂芳基取代的二氢嘧啶类化合物及其在药物中的应用
HK1215030A1 (zh)	2012-11-09	2016-08-12	Indiana University Research And Technology Corporation	用於hbv組裝效應劑的替代用途
SG11201507698QA (en)	2013-03-20	2015-10-29	Univ Indiana Res & Tech Corp	Fluorescent-hap: a diagnostic stain for hbv cores in cells
BR112015028873A2 (pt)	2013-05-17	2017-07-25	Hoffmann La Roche	heteroaril-diidro-pirimidinas interligados na posição 6, para o tratamento e profilaxia de infecção pelo vírus da hepatite b
WO2015074546A1 (en)	2013-11-19	2015-05-28	Sunshine Lake Pharma Co., Ltd.	Dihydropyrimidine compounds and their application in pharmaceuticals
CN104650069B (zh)	2013-11-19	2019-04-19	广东东阳光药业有限公司	4-甲基二氢嘧啶类化合物及其在药物中的应用
CN104650070B (zh)	2013-11-25	2018-09-14	广东东阳光药业有限公司	二氢嘧啶类化合物及其在药物中的应用
KR102284938B1 (ko) *	2013-11-27	2021-08-02	선샤인 레이크 파르마 컴퍼니 리미티드	다이하이드로피리미딘 유도체 및 이의 중간산물의 제조 방법
AU2015226206B2 (en)	2014-03-07	2017-03-16	F. Hoffmann-La Roche Ag	Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of Hepatitis B virus infection
CN106459061B (zh)	2014-05-30	2020-01-21	齐鲁制药有限公司	作为hbv抑制剂的二氢嘧啶并环衍生物

2015
- 2015-03-27 CN CN201510141969.5A patent/CN104945395B/zh active Active
- 2015-03-27 MY MYPI2016702906A patent/MY196243A/en unknown
- 2015-03-27 US US15/116,226 patent/US9771358B2/en active Active
- 2015-03-27 EP EP15769748.3A patent/EP3122747B1/en active Active
- 2015-03-27 KR KR1020167029448A patent/KR20160133563A/ko not_active Withdrawn
- 2015-03-27 CA CA2938050A patent/CA2938050A1/en not_active Abandoned
- 2015-03-27 RU RU2016138735A patent/RU2682672C2/ru active
- 2015-03-27 AU AU2015236982A patent/AU2015236982B2/en active Active
- 2015-03-27 SG SG11201605896WA patent/SG11201605896WA/en unknown
- 2015-03-27 MX MX2016012573A patent/MX2016012573A/es unknown
- 2015-03-27 JP JP2016558407A patent/JP2017512789A/ja active Pending
- 2015-03-27 WO PCT/CN2015/075299 patent/WO2015144093A1/en not_active Ceased

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2014029193A1 (en) *	2012-08-24	2014-02-27	Sunshine Lake Pharma Co., Ltd.	Dihydropyrimidine compounds and their application in pharmaceuticals
WO2014037480A1 (en) *	2012-09-10	2014-03-13	F. Hoffmann-La Roche Ag	6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
光学異性体の分離（季刊化学総説 NO.6）, JPN6011000511, 1989, pages 2 - 5, ISSN: 0003988203 *
加藤隆一: "光学異性薬物の研究の流れ", 薬事, vol. 第２９巻、第１０号, JPN3011000611, 1 October 1987 (1987-10-01), JP, pages 2039 - 2042, ISSN: 0003988202 *
山中宏、宮崎浩、村上尚道: "光学活性体のプレパレーション・生理活性・利用", 季刊化学総説光学異性体の分離, JPN3011000610, 10 June 1999 (1999-06-10), JP, pages 8 - 9, ISSN: 0003988201 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20200032098A (ko) *	2017-06-26	2020-03-25	노스 앤드 사우스 브라더 파마시 인베스트먼트 컴파니 리미티드	디하이드로피리미딘 화합물 및 약제에서의 이의 용도
JP2020525453A (ja) *	2017-06-26	2020-08-27	ノース・アンド・サウス・ブラザー・ファーマシー・インベストメント・カンパニー・リミテッド	ジヒドロピリミジン化合物、及び医薬におけるその使用
JP7260488B2 (ja)	2017-06-26	2023-04-18	サンシャイン・レイク・ファーマ・カンパニー・リミテッド	ジヒドロピリミジン化合物、及び医薬におけるその使用
KR102665544B1 (ko)	2017-06-26	2024-05-14	선샤인 레이크 파르마 컴퍼니 리미티드	디하이드로피리미딘 화합물 및 약제에서의 이의 용도
JP2021523880A (ja) *	2018-05-16	2021-09-09	シチュアンケルン−バイオテックバイオファーマシューティカルカンパニーリミテッド	ジヒドロピリミジン化合物の固体形態及びその調製方法及びその使用

Also Published As

Publication number	Publication date
SG11201605896WA (en)	2016-08-30
CA2938050A1 (en)	2015-10-01
EP3122747A4 (en)	2017-11-15
US20160347746A1 (en)	2016-12-01
KR20160133563A (ko)	2016-11-22
MX2016012573A (es)	2018-02-19
RU2016138735A3 (2)	2018-05-03
CN104945395B (zh)	2018-01-23
CN104945395A (zh)	2015-09-30
AU2015236982B2 (en)	2017-12-14
WO2015144093A1 (en)	2015-10-01
EP3122747A1 (en)	2017-02-01
MY196243A (en)	2023-03-24
EP3122747B1 (en)	2020-05-20
AU2015236982A1 (en)	2016-08-11
RU2016138735A (ru)	2018-05-03
RU2682672C2 (ru)	2019-03-20
US9771358B2 (en)	2017-09-26

Legal Events

Date	Code	Title	Description
2018-03-08	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180308
2018-03-08	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180308
2018-10-16	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181016
2018-10-16	A977	Report on retrieval	Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20181011
2019-01-07	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190107
2019-03-05	A02	Decision of refusal	Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20190305

Publication	Publication Date	Title
RU2682672C2 (ru)	2019-03-20	Соединения дигидропиримидина и их применение в фармацевтических препаратах
RU2678990C1 (ru)	2019-02-05	Соединения дигидропиримидина и их применение в фармацевтических препаратах
RU2655914C9 (ru)	2018-07-24	Соединения дигидропиримидина и их применение в фармацевтических препаратах
KR102667040B1 (ko)	2024-05-20	디하이드로피리미딘 화합물 및 약제에서의 이의 용도
EP3658554A1 (en)	2020-06-03	Dihydropyrimidine compounds and uses thereof in medicine
CN104650070A (zh)	2015-05-27	二氢嘧啶类化合物及其在药物中的应用
CA3079557C (en)	2026-03-17	Dihydropyrimidine compounds and uses thereof in medicine
HK1228400B (en)	2021-01-15	Dihydropyrimidine compounds and their application in pharmaceuticals
HK1228400A1 (en)	2017-11-03	Dihydropyrimidine compounds and their application in pharmaceuticals
HK1224286B (en)	2021-01-29	Dihydropyrimidine compounds and their application in pharmaceuticals
HK1206027B (en)	2018-04-06	2,4,5,6-substituted 3,6-dihydropyrimidine derivatives as hepatitis b virus (hbv) polymerase inhibitors for the treatment of e.g. chronic hepatitis